
Grifois, S.A.
GRFS
GRFS: As a vertically integrated plasma derivative producer, Spain-based Grifols collects plasma and then manufactures and sells plasma-derived products globally. By acquiring Talecris in 2011, Grifols dramatically expanded its plasma-derived product portfolio, and the firm's biopharma business contributed 83% of sales in 2022. Grifols also has smaller segments including diagnostics and biosupplies. Diagnostics is roughly 10% of revenue (following the Biotest acquisition).
moreShow GRFS Financials
Recent trades of GRFS by members of U.S. Congress
Recently reported changes by institutional investors
Quarterly net insider trading by GRFS's directors and management
Government lobbying spending instances
New patents grants
Federal grants, loans, and purchases
Followers on GRFS's company Twitter account
Number of mentions of GRFS in WallStreetBets Daily Discussion
Recent insights relating to GRFS
Recent picks made for GRFS stock on CNBC
ETFs with the largest estimated holdings in GRFS
Flights by private jets registered to GRFS